<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Pre-treatment with angiotensin receptor blockers is known to improve neurological outcome after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated for the first time, whether the renin inhibitor <z:chebi fb="0" ids="601027">aliskiren</z:chebi> has similar neuroprotective effects </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Since <z:chebi fb="0" ids="601027">aliskiren</z:chebi> specifically blocks human renin, double transgenic rats expressing human renin and angiotensinogen genes were used </plain></SENT>
<SENT sid="3" pm="."><plain>To achieve a systolic blood pressure of 150 or 130 mmHg animals were treated with <z:chebi fb="0" ids="601027">aliskiren</z:chebi> (7.5 or 12.5 mg/kg*d) or <z:chebi fb="0" ids="3347">candesartan</z:chebi> (1.5 or 10 mg/kg*d) via osmotic minipump starting five days before middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> with reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> size was determined by magnetic resonance imaging </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="2" ids="33699">mRNA</z:chebi> of inflammatory marker genes was studied in different brain regions </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The mortality of 33.3% (7 of 21 animals) in the vehicle group was reduced to below 10% by treatment with <z:chebi fb="0" ids="3347">candesartan</z:chebi> or <z:chebi fb="0" ids="601027">aliskiren</z:chebi> (p&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="601027">Aliskiren</z:chebi>-treated animals had a better neurological outcome 7 days post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, compared to <z:chebi fb="0" ids="3347">candesartan</z:chebi> (Garcia scale: 9.9±0.7 vs. 7.3±0.7; p&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>The reduction of <z:mpath ids='MPATH_124'>infarct</z:mpath> size in the <z:chebi fb="0" ids="601027">aliskiren</z:chebi> group did not reach statistical significance compared to <z:chebi fb="0" ids="3347">candesartan</z:chebi> and vehicle (24 h post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>: 314±81 vs. 377±70 and 403±70 mm(3) respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>Only <z:chebi fb="0" ids="601027">aliskiren</z:chebi> was able to significantly reduce <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced gene expression of CXC chemokine ligand 1, interleukin-6 and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha in the ischemic core </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Head-to-head comparison suggests that treatment with <z:chebi fb="0" ids="601027">aliskiren</z:chebi> before and during <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> is at least as effective as <z:chebi fb="0" ids="3347">candesartan</z:chebi> in double transgenic rats </plain></SENT>
<SENT sid="11" pm="."><plain>The improved neurological outcome in the <z:chebi fb="0" ids="601027">aliskiren</z:chebi> group was blood pressure independent </plain></SENT>
<SENT sid="12" pm="."><plain>Whether this effect is due to primary anti-inflammatory mechanisms has to be investigated further </plain></SENT>
</text></document>